NEFL and myeloid sarcoma: The most promising paraclinical biomarkers that can feasibly be translated to current clinical practice are serum NfL, thalamic atrophy, chronic active lesions, spinal cord atrophy, GCIPL and RNFL; however, they need to be further validated in longitudinal, long-term studies with larger cohorts of MS patients.